NASHVILLE, Tenn., Oct 13, 2005 /PRNewswire via COMTEX/ -- Spencer Thornton, MD, president of Biosyntrx(R) Inc, an evidence-based company providing nutraceutical products that support the eye and body health today announced the launch of their new product, Zeaxanthin4(TM).
Zeaxanthin is a key dietary molecule that helps protect the macula from blue-light and oxidative damage. Zeaxanthin is suggested in peer-reviewed literature to be the central macula preference over lutein. If the diet is deficient in zeaxanthin, which most diets are, the macula preference for zeaxanthin is so strong the body will attempt to convert a small amount of dietary lutein to a similar molecule called meso-zeaxanthin in an attempt to supply the eye with pigment that best protects the macula.
Each capsule of Zeaxanthin4 contains 4 mg of zeaxanthin supported by 30 mg of fat-soluble vitamin C as ascorbyl palmitate to improve product stability and absorption.
Biosyntrx, founded in late 2002, is a privately held, research-based ophthalmic company incorporated in Lexington, South Carolina. It provides evidence-based nutraceutical products that support optimal eye and body health. The company's previous formulations, BioTears Oral GelCaps(R), Oculair(R) and Macula Complete(R), were developed by physicians and scientists in medicine, nutrition, and health. Biosyntrx nutraceutical formulations are evidence-based and always meet current good manufacturing practice standards (cGMP).
Biosyntrx products are sold with a full money back guarantee. For further information on our products and the thought-leading scientific and medical advisors to the company, please visit www.biosyntrx.com or contact Joe Kirkland, COO at 800-688-6815. For more information on the science behind Zeaxanthin4 contact the Biosyntrx Chief Research Officer, Ellen Troyer, MT MA, in the Colorado Springs, CO research office at 877-327-7889.